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ABSTRACT Murineleukemiaviruses(MuLVs)encodetwoformsofGagpolyprotein:theprecursorfortheviralcoreproteins
(Pr65gagforMoloneyMuLV[M-MuLV])andalongerglycosylatedform(glyco-gag,orgPr80gag).gPr80gagistranslatedfromthe
sameunsplicedviralRNAasPr65gag,fromanupstreamin-frameCUGinitiationcodon.Asaresult,gPr80gagcontains88unique
N-terminalaminoacidsthatincludeasignalpeptidethatconductsgPr80gagintotheroughendoplasmicreticulum,whereitis
glycosylated,exportedtothecellsurface,andcleavedintotwoproteinsof55and40kDa.Theamino-terminal55-kDaprotein
remainscellassociatedwiththe88uniqueaminoacidsexposedtothecytosol.WepreviouslyshowedthatgPr80gagfacilitates
efﬁcientM-MuLVreleasethroughlipidrafts.Inthisreport,wefoundthattheuniqueN-terminaldomainofgPr80gagissufﬁcient
tofacilitateenhancedM-MuLVparticlereleasefromtransfected293Tcells.AsearchforcellularproteinsinvolvedingPr80gag
functionledtocellularLaprotein.OverexpressionofmouseorhumanLaenhancedM-MuLVparticlereleaseintheabsenceof
glyco-gag,andthereleasedvirushadareducedbuoyantdensitycharacteristicofincreasedcholesterolcontent.Moreover,small
interferingRNA(siRNA)knockdownofhumanLaabolishedglyco-gagenhancementofM-MuLVrelease.Theseresultsimplicate
LaasacellularproteininvolvedinM-MuLVglyco-gagfunction.WealsofoundthatoverexpressionofmouseorhumanLacould
enhanceHIV-1releaseintheabsenceofgPr80gag.Therefore,M-MuLVandHIV-1mayshareapathwayforreleasethroughlipid
raftsinvolvingLa.
IMPORTANCE RetrovirusescausediseasessuchasleukemiaandAIDS.Animportantaspectofviralreplicationishowvirusesare
releasedfrominfectedcells.Wepreviouslyfoundthatauniqueproteinencodedbymurineleukemiaviruses(MuLVs),glyco-gag
(orgPr80gag),enhancesefﬁcientvirusreleasethroughcholesterol-richmembranesubdomainscalledlipidrafts.Inthisstudy,we
foundthattheN-terminaldomainofgPr80gagissufﬁcienttoenhanceviralrelease.Asearchforcellularproteinsthatparticipate
ingPr80gagfunctionledtocellularLaprotein.OverexpressionofLaphenocopiedglyco-gaginenhancingM-MuLVrelease,and
knockdownofLaabolishedglyco-gagfunction.M-MuLVglyco-gagalsoenhancedreleaseofHIV-1,asdidoverexpressionLain
theabsenceofglyco-gag.Thus,M-MuLVandHIV-1mayshareacellularpathwayforreleasethroughlipidraftsinvolvingLa.
Theseresultsmayalsoberelevantforothervirusesthatarereleasedthroughlipidrafts.
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M
urine leukemia viruses (MuLVs) are prototypical simple
retroviruses of the gammaretrovirus genus. One unique
feature of MuLVs and many other gammaretroviruses is that
they encode an alternate form of Gag polyprotein, gPr80gag (or
glyco-gag), as well as the polyprotein precursor to Gag struc-
tural proteins, Pr65gag. gPr80gag is translated from unspliced
viralmRNAviaanupstreamCUGinitiationcodoninthesame
reading frame as for Pr65gag (1–3). The N terminus of gPr80gag
contains88uniqueaminoacids,includingasignalpeptidethat
targets gPr80gag for transport into the rough endoplasmic re-
ticulum, leading to its glycosylation and export to the cell sur-
face (4). At the cell surface, mature gPr80gag is cleaved into two
proteins of ca. 55 and 40 kDa (1, 5), and the 55-kDa amino-
terminal portion is maintained in a type II integral membrane
conﬁguration, with the 88 unique amino acids in the cytosol
(4).
Glycosylated Gag proteins are conserved among gammaretro-
viruses, but the molecular functions of these proteins have been
unclear until recently. In mice, gPr80gag is a major pathogenic
determinant for neuropathic MuLV (6–9). MuLV mutants of
gPr80gag show substantial replication defects in mice, and there is
strong selection for recovery of gPr80gag expression (10–12). We
previously showed that gPr80gag plays a role in a late step in viral
assemblyorrelease.gPr80gag-negativeMuLVsbudfromcellsfrom
aberrant tube-like structures (12, 13). Expression of gPr80gag in
mutant-infectedcellsincreasesvirusparticlerelease,andthetube-
like structures are replaced by typical spherical particles (12). Re-
cently, we found that there are two pathways for MuLV release
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and interferon-resistant release through areas other than lipid
rafts (14). gPr80gag facilitates viral release through lipid rafts, and
this is apparently the more efﬁcient pathway for release. We also
found that Moloney MuLV (M-MuLV) gPr80gag can facilitate re-
lease of HIV-1 particles (14). It has also recently been reported
that gPr80gag can complement a replication defect in human lym-
phocyte lines for Nef-deﬁcient HIV-1, although in this study the
effect of glyco-gag was on viral infectivity as opposed to viral re-
lease (15).
Inthisreport,weshowthattheunique88aminoacidsattheN
terminus of gPr80gag are sufﬁcient for facilitating MuLV and HIV
release through lipid rafts. Moreover, we have identiﬁed the cel-
lularproteinLa/SSB(Sjogren’ssyndromeautoantigenB)asbeing
involved in the mechanism of gPr80gag action.
RESULTS
TheN-terminaluniqueregionofgPr80gagissufﬁcientforactiv-
ity. In our previous studies, we showed that expression of
M-MuLV gPr80gag from the expression plasmid p8065-2 en-
hances M-MuLV particle release from NIH 3T3 ﬁbroblasts and
thatthiswasdonebydirectingreleasethroughlipidrafts,sincethe
resulting particles had higher cholesterol content, reduced buoy-
ant density, and enhanced association with cellular detergent-
resistant membranes (DRMs) (14). Enhancement of virus release
was also found in transiently transfected 293T cells (14). Since
gPr80gag differs from Pr65gag by additional amino-terminal resi-
dues, we tested whether this unique region was sufﬁcient for
gPr80gag activity. An expression plasmid encoding the unique 88
amino-terminal sequences of gPr80gag fused to an N-terminal
hemagglutinin (HA) epitope tag (HA-gg88) was generated
(Fig. 1). As shown in Fig. 2A, when HA-gg88 or p8065-2 was
cotransfected into 293T cells along with an M-MuLV gag-pol ex-
pression construct (AKAQ188), equivalent amounts of intracel-
lular Gag protein were detected. Like p8065-2, HA-gg88 also fa-
cilitated virus release, in fact somewhat more effectively than
p8065-2 (ca. 3-fold and 4.5-fold increases, respectively). In the
absence of HA-gg88 or p8065-2, release of virions from
AKAQ188-transfected cells was inefﬁcient (but detectable), while
the amount of cytoplasmic Gag protein produced was similar.
To test whether HA-gg88 also facilitates virus release through
lipid rafts, we tested for the presence of Pr65gag in cellular DRMs
that are cholesterol rich as described previously (14). As shown in
Fig.2BandC,p8065-2resultedinaca.3-foldincreaseinPr65gagin
DRMs (as reported previously [14]), and HA-gg88 had an equiv-
alent effect. The proportions of Pr65gag in DRMs for the tran-
siently transfected 293T cells were less than those for NIH 3T3
ﬁbroblasts infected with wild-type versus glyco-gag-negative
M-MuLV (14), but the relative differences were similar. As a sec-
ond measure of release through lipid rafts, we tested the buoyant
densitiesoftheresultingvirusesinsucrosegradients.Asshownin
Fig. 2D, virions released from p8065-2 or HA-gg88-expressing
cells both showed lower buoyant densities, characteristic of vi-
ruses with higher cholesterol content, than virus released from
293T cells in the absence of glyco-gag. The absolute values of the
buoyant densities reported here were somewhat lower than those
in our previous study (14), which was due to a change in the
method for measurement of sucrose densities, but the relative
differencesbetweencontrolvirionsandthosereleasedfromglyco-
gag-expressing cells were equivalent. Thus, HA-gg88 was as efﬁ-
cient as p8065-2 in directing virus release through lipid rafts, in-
dicatingthattheN-terminaluniqueregionofgPr80gagisnecessary
and sufﬁcient for the activity of this protein.
Expression of HA-gg88 relocalizes cellular La protein to the
cytoplasm. To investigate the mechanism of gPr80gag action, a
yeast two-hybrid screen was conducted as described in Materials
and Methods. The bait plasmid encoded the 88 amino-terminal
uniqueaminoacidsfusedtotheLexADNAbindingdomain.This
plasmid was used to screen a mouse cDNA expression library
fused to the B42 activation domain in Saccharomyces cerevisiae.
FourcDNAfusionclonesthatshowedstronginteractionwiththe
bait plasmid were identiﬁed, and sequencing of the inserts indi-
cated that they all were cDNAs for Sjogren’s syndrome nuclear
autoantigen 1 (SSNA1; also known as nuclear autoantigen 14
[NA14][16,17]).WhiletheinitialreportdescribedSSNA1/NA14
asanuclearantigen,subsequentstudiesindicatedthatitpredom-
inantlybindstocentrosomesinthecytoplasm(16–18).Totestfor
potentialinvivointeractionsbetweenNA14andgPr80gag,weper-
formedtwo-colorimmunoﬂuorescencemicroscopyon293Tcells
transfected with HA-gg88 (Fig. 3). Endogenous NA14 showed a
cytoplasmic perinuclear location consistent with centrosomes
reminiscentofpreviousstudies(16,18),regardlessofwhetherthe
cells were expressing HA-gg88 or not. HA-gg88 was found in the
cytoplasm and localized mainly in the perinuclear region sur-
roundingtheendogenousNA14protein.However,thesetwopro-
teinsdidnotshowactualcolocalization.NIH3T3cellstransiently
transfected with an epitope-tagged Flag-NA14 protein showed
sporadic localized signals in the cytoplasm as well as the con-
densed signals at perinuclear regions, but in cotransfections with
HA-gg88, colocalization with Flag-NA14 was not observed (not
shown). Glutathione S-transferase (GST) pulldown experiments
with293TcellscotransfectedwithaGST-taggedgg88proteinand
Flag-NA14 also did not show evidence of direct binding between
these two proteins (not shown). Thus, despite the two-hybrid re-
sults, gg88 does not appear to directly bind NA14 in mammalian
cells.
Because the major Sjogren’s syndrome autoantigens are asso-
ciatedwithimmuneresponsesandviralreplication,wealsotested
FIG 1 Expression plasmids used. Diagrams of the M-MuLV expression plas-
mids used in these experiments are shown. AKAQ188 has deletions in the
regionencodingtheleaderpeptide(deletionofpositions215to561),contain-
ing both the packaging signal (positions 217 to 567) (46) and the CUG initia-
tioncodonforgPr80Gag(positions357to359),andintheenvgene(deletionof
positions5819to7197).TheCUGstartcodonforgPr80gagwasreplacedbyan
AUG start codon in both p8065-2 and HA-gg88. In HA-gg88, viral sequences
upstreamoftheCUGcodonwerealsoremovedsothatthisplasmidwouldlack
a functional packaging sequence (46). LTR, long terminal repeat; CMV-P,
cytomegalovirus promotor.
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rect) with other Sjogren’s syndrome autoantigens (SSA [also
known as Ro] and SSB [also known as La, or the lupus antigen]).
Roisamemberofthetripartitemotif(TRIM)proteinfamily;this
protein is an interferon-inducible E3 ligase that ubiquitinates in-
terferon regulatory factor 3 (IRF-3) and IRF-8 (19–21). La is a
predominantly nuclear RNA binding protein that binds certain
RNApolymeraseIII(PolIII)transcripts,facilitatingtheirprocess-
ing and trafﬁcking (22, 23); it also facilitates replication of some
viruses (24–30). Two-color immunoﬂuorescence microscopy for
RoandHA-gg88wascarriedoutwith293Tcells.Fortheseexper-
iments, it was necessary to transfect cells with a Ro expression
plasmidsinceendogenousRoproteincouldnotbedetectedbythe
anti-Ro antibody. 293T cells were cotransfected with the Ro ex-
pression plasmid and either pcDNA3.1 or HA-gg88. Ro protein
was found in both the cytoplasm and the nucleus (more in the
cytoplasm) (data not shown), and the distribution pattern was
consistent with previously published studies (31, 32). However,
coexpression of HA-gg88 did not change the cellular distribution
of Ro, and colocalization of HA-gg88 and Ro was not observed
(data not shown).
In contrast, expression of HA-gg88 affected the intracellular
localizationofLa(Fig.4).In293TorNIH3T3culturestransfected
with HA-gg88 (Fig. 4, second row and bottom row), La showed
nuclear ﬂuorescence in the cells that did not express HA-gg88,
while the cells that were positive for HA-gg88 showed substantial
cytoplasmic ﬂuorescence for La. One possible explanation for the
resultsisthattransfectionofanyexpressionplasmidcouldleadto
relocalizationofLainthosecellsthattookuptheDNA.However,
incellstransfectedwiththeJSRV,jaagsiektesheepretrovirus,Env
FIG2 The 88 amino acids at the amino terminus in gPr80Gag facilitates M-MuLV particle release through lipid rafts. The M-MuLV Gag-Pol expression vector
was transfected with p8065-2 and HA-gg88 into 293T cells. (A) The cells and media were harvested at 48 h posttransfection, and the same portion of cells and
viruses were subjected to the Western blots with anti-p30CA and anti--Tubulin (loading control). (B) The cell lysates prepared from the transfected 293T cells
with the lysis buffer containing 1% Triton X-100 were analyzed by membrane ﬂoatation in 5 to 30% sucrose gradients. Low-density fractions represented
detergent-resistant membranes (DRM) and lipid rafts, while high-density fractions represented protein in detergent-soluble membranes (DSM) or cytosolic
proteins. (C) The amount of Pr65gag was quantiﬁed by densitometry, and the relative amount of Pr65 in lipid rafts to control are shown (means  standard
deviations[SD]).(D)Virusesharvestedfromthetransfected293Tcellswereanalyzedbydensitygradientcentrifugation,anddistributionofp30CAwasanalyzed
by Western blotting and densitometry.
M-MuLV Glycosylated Gag and La
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with the backbone pcDNA3 expression plasmids (not shown), La
localizationwaslargelynuclear.Whentheresultswerequantiﬁed,
43.5% of 293T cells from HA-gg88-transfected cultures showed
cytoplasmicLastaining,versus18.6%showingcytoplasmicstain-
ing, after GP-HA transfection. Likewise, NIH 3T3 cultures
transfected with HA-gg88 showed cytoplasmic staining in 27.5%
of cells, compared to 6.2% for GP-HA-transfected cells. Taken
together, these results indicated that HA-
gg88 relocalizes La to the cytoplasm, which
suggested that cytoplasmic La might play a
role in the mechanism of glyco-gag action.
Overexpression of La phenocopies gly-
cosylated gag. If M-MuLV glyco-gag facili-
tates virus release via La protein, one mech-
anism could be that when La is directed to
the cytoplasm by glyco-gag, La plays a posi-
tive role in facilitating virus release through
lipid rafts. We reasoned that overexpression
of La might result in enhanced cytoplasmic
levels of the protein, which might facilitate
virus release in the absence of glyco-gag ex-
pression.AsshowninFig.5A,cotransfection
of 293T cells with expression plasmids for
mouse or human La along with AKAQ188
resulted in signiﬁcantly enhanced virus re-
lease, with human La more effective than
mouse La (ca. 3-fold and 6-fold increases,
respectively). Overexpression of mouse La
also enhanced the appearance of Pr65gag in
cellular DRMs (Fig. 5B and C), and virus re-
leased from cells overexpressing mouse La
showed the characteristic shift to lighter
buoyant density, indicative of higher choles-
terol content. Thus, in the absence of glyco-
gag,overexpressionofLaappearstoresultin
the same enhancement of virus release
through lipid rafts as that seen when glyco-
gag is expressed.
Knockdown of La antagonizes the ef-
fects of HA-gg88. While the effects of over-
expressing La were consistent with the idea
that glyco-gag functions through La, we
sought additional support for this model.
We tested whether knockdown of human La
would reduce HA-gg88-enhanced virus re-
lease from transfected 293T cells. As shown
FIG3 LocalizationofHA-gg88,NA14,andRo.The293TcellsweretransfectedwithHA-gg88.Thetransfectedcellswereﬁxedat36to48hposttransfectionwith
paraformaldehydeandthenincubatedwithanti-HAandanti-NA14antibodies.Theantigensandnucleiwerevisualizedbysecondaryantibodiesconjugatedwith
Alexa488,Alexa546,andDAPI(4=,6-diamidino-2-phenylindole).ThepanelsforNA14-DAPIandHA-DAPIandamergeoftheﬁrsttwopanelsareshown.The
inserts are enlarged images and are shown next to the merge picture.
FIG 4 Relocalization of La by HA-gg88. The 293T and NIH 3T3 cells were transfected with
HA-gg88andtheJSRVEnv-expressingvectorGP-HA(transfectioncontrol).Thetransfectedcells
were ﬁxed at 36 to 48 h posttransfection with paraformaldehyde and then incubated with anti-HA
and anti-La antibodies. The antigens were visualized by the secondary antibodies conjugated with
Alexa 488 and Alexa 546. The panels for La, HA, and a merge (La-HA-DAPI) are shown.
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with or without HA-gg88, as well as two small interfering RNAs
(siRNAs) against human La. The siRNAs were effective in reduc-
ing the amount of La present in the cells (Fig. 6, third panel from
the top). As shown in the second panel, in the absence of the
siRNAs, HA-gg88 substantially enhanced virus release; both siR-
NAs signiﬁcantly reduced this enhancement. On the other hand,
the lower levels of virus released in the absence of HA-gg88 were
not affected by knockdown of La. Therefore, the effects of La
knockdown were speciﬁc to glyco-gag-enhanced virus release. As
shown in the top panel of Fig. 6, neither HA-gg88 nor anti-La
siRNAs affected the amount of intracellular Pr65gag.
OverexpressionofLaresultsininterferon-sensitivevirusre-
lease. In our previous study, one of the ﬁrst indications that
gPr80gagdirectsM-MuLVreleasethroughlipidraftswasthatwild-
type-M-MuLV release was sensitive to mouse IFN-A (IFN-)
but that gPr80gag-negative-virus release was largely resistant to it
(14). Therefore, we tested whether the enhanced virus release re-
sulting from overexpression of La is sensitive to IFN-. As shown
in Fig. 7, 293T cells were transiently transfected with AKAQ188
along with either HA-gg88 or the mouse La expression plasmid.
ThetransfectedcellsweretreatedwithdifferentdosesofIFN-for
24 h, and viruses were gathered after8ho ffurther incubation. As
FIG 5 Overexpression of La facilitates M-MuLV particle release through lipid rafts. The M-MuLV gag-Pol expression vector (AKAQ188) was transfected with
mouse La and human La expression vectors into 293T cells. The assessment for viral release (A), the distribution of Pr65gag in DRM (B and C), and the density
of released viruses from the transfected cells (D) are described in the legend to Fig. 2.
FIG 6 Interference of La expression antagonizes HA-gg88 in M-MuLV par-
ticlerelease.M-MuLVGag-Polexpressionvectoristransfectedinto293Tcells
with or without HA-gg88. At 24 hours posttransfection, siRNAs against hu-
manLa(no.5andno.10)weretransfected.TwodaysaftersiRNAtransfection,
media were replaced, and then the cells and media were harvested after8ho f
furtherincubation.Thesameportionofcellsandvirusesweresubjectedtothe
Westernblotswithanti-p30CA,anti-La,andanti--Tubulin(loadingcontrol).
NSP, non-speciﬁc signals.
M-MuLV Glycosylated Gag and La
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with HA-gg88 was inhibited by IFN- treatment (Fig. 7, middle
panels),whilethesmalleramountsofvirusreleasedfromthecon-
trol cells (left panels) were not affected by IFN-. (Longer phos-
phorimager exposures were required for the left panels due to the
lower levels of virus released.) As shown in the right panels, the
enhancedvirusreleaseresultingfromoverexpressionofmouseLa
was also inhibited by IFN- treatment. Thus, the enhanced virus
release mediated by La overexpression is IFN sensitive.
HA-gg88 and La overexpression both enhance release of
HIV.WepreviouslyshowedthatgPr80gagcanalsoenhancerelease
of another retrovirus, HIV-1, from transfected 293T cells (14). As
shown in Fig. 8A, HA-gg88 also enhanced release of HIV-1 parti-
cles from 293T cells transiently transfected with an HIV-1 gag-pol
expression vector, with HA-gg88 showing slightly higher efﬁ-
ciency than p8065-2 (ca. 3-fold and 4.5-fold increases, respec-
tively). Overexpression of either mouse or human La also en-
hanced HIV-1 particle release (Fig. 8B), with human La again
showingastrongereffectthanmouseLain293Tcells(ca.3.5-fold
and 7-fold increases, respectively). Thus, the amino-terminal
unique region of gPr80gag is also sufﬁcient for enhancement of
HIV-1 particle release, and glyco-gag enhancement of HIV-1 re-
lease is likely mediated through La.
DISCUSSION
In this report, we have obtained insights into the mechanism of
action for MuLV-glycosylated Gag protein. We found that the
N-terminal unique 88 amino acids of gPr80gag are necessary and
sufﬁcient for the ability of gPr80gag to target release through lipid
rafts, as evidenced by the enhanced association of the Gag
polyprotein precursor Pr65gag with detergent-resistant mem-
branes,thelowerbuoyantdensityofreleasedvirions(reﬂectiveof
ahighercholesterolcontent),andthesensitivityofvirusreleaseto
interferon. A search for cellular proteins that interact with glyco-
gag led indirectly to the cellular La protein, and HA-gg88 was
found to relocalize La into the cytoplasm from the nucleus. Over-
expression of La in transfected 293T cells phenocopied glyco-gag
in all measures tested. Moreover, knockdown of La with siRNAs
abrogated the ability of HA-gg88 to enhance MuLV virus particle
release. These results strongly support a role for La in the mecha-
nism of glyco-gag action, with La being a downstream effector of
glyco-gag.
FIG 7 Effect of IFN- on virus release from 293T cells overexpressing HA-gg88 and mouse La. The 293T cells were transiently transfected with M-MuLV
Gag-Pol expression vector with HA-gg88 and a mouse La expression vector. The cells were treated with different concentrations of IFN- for 24 h, after which
mediawerereplaced,andthecellsandreleasedviruseswerecollectedafter6hoffurtherincubation.Thesameportionsofcellsandvirusesweresubjectedtothe
Western blot analyses with anti-p30CA.
FIG8 OverexpressionofHA-gg88andLaincreasestheefﬁciencyofHIV-1particlerelease.TheHIV-1Gag-Polexpressionvectorwastransfectedinto293Tcells
with p8065-2 and HA-gg88 (A) or mouse La and human La expression vectors (B). The cells and media were harvested at 48 h posttransfection, and the same
portion of cells and viruses were analyzed by Western blotting with anti-HIV p24C and anti--Tubulin (loading control).
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nantly localized in the nucleus. The best known function of this
protein is to bind the 3= ends of RNA transcripts containing U
residues, notably tRNA precursors and other RNA Pol III tran-
scripts(22,23).Thisbindingprotectspre-tRNAsfrompremature
3= end processing, allowing for proper maturation. Substantial
structural and functional studies have been conducted on La (22,
23).OtherfunctionsalsohavebeenreportedforLa.Itbindstothe
genomic RNAs for several cytoplasmic RNA viruses, including
poliovirus(33),coxsackievirusB3(28)(picornaviruses),andhep-
atitis C virus (a ﬂavivirus) (25), and the binding is important for
the function of the viral internal ribosome entry sites (IRES). The
latterobservationsmakeseveralpoints.First,Laproteincanfunc-
tion in the cytoplasm as well as in the nucleus. Second, it seems
likely that La may interact with other cellular proteins in carrying
out its various functions. Third, other viruses have also employed
La protein to carry out key parts of their replication cycles. Thus,
while at ﬁrst surprising, the involvement of La in glyco-gag’s en-
hancement of MuLV release is reasonable.
While these studies have established a role for La in glyco-gag
function, the mechanism of action remains to be determined. We
havenotdetecteddirectinteractionbetweenHA-gg88andLapro-
tein in pulldown assays from transfected cells (T. Nitta and R.
Tam,unpublished),whichmightsuggestthatglyco-gagandLaare
interacting indirectly through another cellular protein(s) or par-
ticle. This notion is also consistent with the ﬁndings that neither
gPr80gag nor La is found in DRMs from transfected cells, even
though the DRMs from such cells contain enhanced levels of
Pr65gag when either glyco-gag or La is expressed along with a gag-
polexpressionvector.Thus,wehypothesizethatglyco-gagandLa
facilitate release through lipid rafts by interacting with other pro-
teins or macromolecules that conduct Pr65gag to the DRMs/lipid
rafts. It will be of substantial interest to identify such proteins or
macromolecules. The results also indicated that human La was
more efﬁcient than mouse La in enhancing virus release from
293T cells. These cells are of human origin, which might suggest
that there is species preference between La proteins and the cellu-
lar factors that they interact with for enhancing virus release.
SinceLaisanRNAbindingprotein,itwillbeinterestinginthe
future to test whether the RNA binding activity is important for
enhancement of virus release. When retroviruses are assembled,
this involves interaction at membranes of the gag and gag-pol
polyproteins, the genomic RNA, and the envelope protein. One
possibility is that La is interacting with genomic RNA and facili-
tating incorporation into virus particles. However, the experi-
ments presented here were with transiently transfected 293T cells
expressing only Gag and Gag-pol polyproteins, with no Env pro-
teinorpackageableviralRNA.Othershavepreviouslyshownthat
MuLV particles consisting of Gag and Gag-pol proteins can be
assembled and released from cells in the absence of viral genomic
RNA or Env protein (34, 35). Thus, interaction of La with viral
RNA is not involved in the release through lipid rafts shown here.
Previous reports by chemical analyses (4, 36) and computer
predictions(notshown)indicatedthatgPr80gagisatypeIIintegral
membrane protein with a short amino-terminal cytoplasmic se-
quence. Here, we made HA-gg88, containing the initial 88 amino
acidsofgPr80Gag,andthistruncatedproteinshowedactivitysim-
ilar to that of the entire gPr80Gag protein in enhancing M-MuLV
release through lipid rafts (Fig. 2), suggesting that neither the gly-
cosylations on the p15MA and p30CA regions (36) nor any of the
extracellular Gag residues are required for viral release enhance-
ment. HA-gg88 distributes in the cytoplasm, mainly at perinu-
clear regions. Similar to the results reported here, a truncated
gPr80gag containing the amino-terminal 189 amino acids showed
stronglocalizationatperinuclearregions(15).Thus,extracellular
Gagresidues,includingthosefromposition89toposition189,do
not determine the perinuclear localization.
We previously showed that MuLV gPr80gag also enhances re-
lease of HIV particles through lipid rafts (14). Pizzato (15) has
recently shown that MuLV glyco-gag complements a replication
detectforNef-negativeHIVinlymphocytes,althoughinthelatter
study the major glyco-gag effect was on Nef-negative viral infec-
tivity as opposed to release. The glyco-gag effects of Nef-negative
HIV infectivity were found to be most pronounced for infected
lymphocyte cell lines, while less pronounced for other cell lines,
suchas293T,andevenlessforsomeﬁbroblastlines.Therelation-
ships of glyco-gag effects on viral infectivity from lymphocytes
and particle release from 293T cells as described here and from
NIH 3T3 cells in our previous study (14) remain to be elucidated.
TheresultsshownherealsodemonstratethatoverexpressionofLa
canphenocopytheenhancedvirusreleaseforHIVparticles.Thus,
La appears to be involved in facilitating HIV release through lipid
rafts as well. It will interesting to test whether more-distantly re-
lated viruses that exit cells through lipid rafts employ a similar
mechanism.
Extensive research has been conducted on HIV and MuLV
assembly in infected cells. The interaction of Gag L domains
(through motifs such as PS/TAP or YPDL) with components of
thecellularvesiculartrafﬁckingmachinery(e.g.,ESCRTproteins)
results in transport of Gag polyprotein to the plasma membrane
or maybe internal sites of assembly (e.g., multivesicular bodies)
(37–40).ItdoesnotseemlikelythatLdomainsofGagpolyprotein
and the resulting association with the vesicular trafﬁcking ma-
chineryaresufﬁcientfortargetingvirusreleasethroughlipidrafts.
Infact,theGagpolyproteinproducedinagPr80gagmutantMuLV
isidenticaltothatofwild-typevirus,withthesameLdomains(41,
42). Thus, transport of Gag polyprotein (Pr65gag) to the plasma
membraneshouldnotbeaffectedbygPr80gagstatus.Rather,once
Gag polyprotein arrives at the plasma membrane MuLV, glyco-
gag, working through La, may then conduct it to DRMs and lipid
rafts, where efﬁcient virus release occurs.
MATERIALS AND METHODS
Cells. Human 293T and mouse NIH 3T3 ﬁbroblasts were grown in Dul-
becco’s modiﬁed Eagle’s medium supplemented with penicillin (100 U/
ml), streptomycin (100 mg/ml), and 10% fetal bovine serum (293T cells)
or 10% calf serum (NIH 3T3 cells).
DNAconstructs.Theplasmidp8065-2,expressingMuLVgPr80gag,was
described previously (Fig. 1) (12). To make the plasmid HA-gg88, which
expresses an HA epitope tag and the 88 amino acids at the N terminus of
gPr80gag, the tetherin-coding sequence was removed by digesting HA-
tetherin (43) with EcoRI and NotI. The region encoding the N-terminal
88 amino acids was ampliﬁed from p8065-2 by PCR with primers 5=-TCCC
CGGAATTCCTCGAGGCCACCATGGGAGACGTCCCAGGGAC and 5=-
TCCCCGGCGGCCGCCTAATTCTCAGACAAATACAGAAAC. The am-
pliﬁed PCR product was digested with EcoRI and NotI and was ligated with
the backbone of the digested HA-tetherin plasmid. For assessment of viral
release from cells transiently transfected with retroviral constructs carrying
gag and pol, the gPr80gag-negative M-MuLV Gag-Pol expression vector
AKAQ188 (Fig. 1) and the HIV-1-based packaging vector pCMV-dR8.74
(http://www.lentiweb.com/) were used. The plasmids pcDNA3 (Invitrogen)
and pEGFP-N1 (Clontech) were used as negative controls and also added to
M-MuLV Glycosylated Gag and La
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NA14,SSA/Ro,andSSB/LaandmouseSSB/LawereobtainedfromOpenBio-
systems. For the bait plasmid in yeast two-hybrid screening, the gPr80gag
unique region at the N terminus of gPr80gag was ampliﬁed with the
primers5=-GCCGAATTCATGGGAGACGTCCCAGGGACTTCGand5=-G
CCGTCGACTCAATTCTCAGACAAATACAGAAACAC. The PCR prod-
uct was digested with EcoRI and SalI and ligated with similarly digested
pEG202-LexAtoexpressgg88fusedtoLexADNAbindingprotein.Theplas-
mid GP-HA, expressing JSRV Env with the HA epitope tag from the cyto-
megalovirus promoter, was described previously (44).
Antibodiesandchemicals.Rabbitpolyclonalanti-MuLVp30CAanti-
serum was described previously (45). Mouse monoclonal anti-HIV-1
p24CA antibody (YDHIVgp24) was purchased from MyBioSource. For
detection of epitope tags, mouse and rabbit anti-HA antibodies (Cell Sig-
naling), anti-HA antibodies conjugated with horseradish peroxidase
(HRP; GenScript), and anti-Flag antibodies (Cell Signaling) were used.
The antibodies against Ro (D-12) and NA14 were purchased from Santa
CruzBiotechnologyandProteinTechGroup.TodetectLa,mousemono-
clonal anti-La antibodies (312B; Santa Cruz Biotechnology) and rabbit
polyclonalanti-Laantibodies(Abgent)wereused.Beta-Tubulinwasused
for the loading control in Western blots and was detected by rabbit anti-
beta-Tubulin(CellSignaling).ForWesternblots,weusedanti-mouseIgG
conjugated with horseradish peroxidase (Thermo Scientiﬁc) and anti-
rabbit IgG conjugated with horseradish peroxidase (GE Healthcare). For
indirect ﬂuorescence microscopy, anti-mouse and anti-rabbit IgGs con-
jugated with Alexa 488 or 546 (Invitrogen) were used. Mouse alpha A
interferon (IFN-A) was obtained from Calbiochem.
Indirect immunoﬂuorescence microscopy. The 293T and NIH 3T3
cells were plated on glass coverslips 1 day before transfection. The cells
were transfected with HA-gg88, a Ro-expressing vector, and pcDNA3 by
Lipofectamine 2000 (Invitrogen) or BioT (Bioland) and then were incu-
bated for 36 to 48 h. The cells were ﬁxed with 4% paraformaldehyde for
30 min at room temperature. After the cells were washed and blocked,
antibodies were added. The cells were stained with ﬂuorescence-
conjugatedsecondaryantibodies,followedbymountingwithVectashield
mountingmedium(VectorLaboratories).Theimageswereanalyzedwith
Axiovert200 and LSM510 microscopes (Carl Zeiss).
Yeast two-hybrid screening. To ﬁnd cellular proteins binding to the
gPr80gag-uniqueaminoacidsattheNterminusofgPr80gag,weconducted
the yeast two-hybrid screen using pLexA-gg88 and a mouse liver cDNA
library. The bacterial strain XL-1-Blue (supE44 hsdR17 recA1 endA1
gyrA46 thi relA1 lac) and the Saccharomyces cerevisiae strain EGY48
[MAT his3 trp1 ura3-52 leu::pLeu-LexAop6/Psh18-34 (LexA-op-lacZ re-
porter)] were used. The Saccharomyces cerevisiae strain EGY48 was se-
quentially cotransformed with pLexA-gg88 and the cDNA library and
then plated on medium lacking uracil, histidine, and tryptophan (SD/
U, H, W). After the resulting colonies were harvested and pooled,
approximately 5  106 colonies were replated in selection medium lack-
ing uracil, histidine, tryptophan, and leucine (SD/ U, H, W, L)
and containing 2% galactose to induce the expression of cDNAs. The
resulting colonies were streaked on the X-Gal (5-bromo-4-chloro-3-
indolyl--D-galactopyranoside)-containing medium (SD/ U, H,
W) to identify and eliminate false positives.
Flotation of DRM domains. Flotation of DRMs was performed as
previouslydescribed(14),withslightmodiﬁcations.293Tcellstransiently
transfected with AKAQ188, p8065-2, HA-gg88, a mouse La expressing-
vector, and control vectors (pCDNA3 or pEGFP-N1) were treated on the
dish with lysis buffer (0.8 ml/10-cm dish) containing 25 mM Tris-HCl
(pH 8.0), 140 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM phenyl-
methylsulfonylﬂuoride(PMSF),1mMNa3VO4,andaproteaseinhibitor
cocktail (Roche) for 20 min at 4°C. The lysates were harvested and then
centrifuged at 10,000  g for 5 min at 4°C. The postnuclear lysate was
adjusted to 40% (wt/vol) sucrose, and thena5t o3 0 %discontinuous
sucrose gradient was layered on the top. Samples were centrifuged at
100,000gfor18to24hat4°C.Thefractionswerecollectedfromthetop
ofthegradienttube.Thedensitiesofthefractionatedsamplesweredeter-
mined by use of a refractometer.
KnockdownofLaexpressionbysiRNA.InterferenceofLaexpression
wasconductedbysiRNAs.The293Tcellson6-wellplatesweretransfected
withAKAQ188andHA-gg88orcontrolvectorsbyuseofaCalPhosmam-
maliantransfectionkit(Clontech).At24hoursposttransfection,twodif-
ferent siRNAs against human La (no. 5 and no. 10; Qiagen) were trans-
fected at 10 M by use of Lipofectamine RNAiMAX (Invitrogen).
Two days after siRNA transfection, media were replaced, and then the
cells and media were harvested after8ho ffurther incubation.
IFN treatment and detection of viruses. Treatment of IFN- and
detection of released viruses and viruses in cells by anti-p30CA antibodies
were described previously (14).
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